Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesAequus Pharmaceuticals Inc

Aequus Pharmaceuticals Inc

Healthcare Drug Manufacturers - Specialty & Generic
PortfolioPortfolio WatchlistWatchlist
Company price
None CAD 0.00(0%)
Last update at 2026-05-14T21:00:15.724128Z
Market Cap
0.66M

Momentum Score

…

Aequus Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada. The company offers ZIMED PF, a preservative-free bimatoprost prescription drug for the for the reduction of elevated interocular pressure in patients with open angle glaucoma or ocular hypertension. It also develops REV-0100, which is in pre-clinical trial for the treatment of stargardt disease. Aequus Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in Vancouver, Canada.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

52 Week Price Range
0.01
Low
0.01
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High

Key Metrics*

Previous Close
-
Dividend Yield
-
Revenue TTM
0.92M
Revenue Per Share
0.01
Gross Profit TTM
0.52M
Debt / Equity
-1.18
ROE
-1569.60%
Net Debt
5.98M
ROCE
35.48%
Diluted EPS TTM
-0.02

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly yearly yearly
Date 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Income before tax -2.18M -2.96M -3.21M -1.81M -1.05M
Net income -2.18M -2.96M -3.21M -1.81M -1.05M
Selling general administrative 2.33M 2.17M 2.98M 3.63M 2.96M
Selling and marketing expenses - 0.36M 0.49M - -
Gross profit 0.33M 0.01M 1.15M 2.69M -
Reconciled depreciation 0.13M 0.14M 0.13M 0.13M 0.21M
Ebit - -2.82M -2.50M -1.61M -0.78M
Ebitda - -2.68M -2.37M -1.23M -0.31M
Depreciation and amortization - 0.14M 0.13M - -
Operating income -2.13M -2.82M -2.50M -1.37M -0.53M
Other operating expenses - 3.08M 3.88M - -
Interest expense 0.25M 0.15M 0.21M 0.45M 0.52M
Interest income 0.00M 0.00M 0.02M 0.01M 0.00M
Net interest income -0.25M -0.14M -0.19M -0.44M -0.52M
Income tax expense - -0.00M -0.00M - -
Total revenue 0.58M 0.25M 1.38M 2.71M 2.59M
Total operating expenses 2.71M 2.83M 3.64M 4.08M 3.12M
Cost of revenue 0.25M 0.25M 0.23M 0.03M -
Total other income expense net 0.20M -0.14M -0.71M -0.00M -0.00M
Net income from continuing ops -2.18M -2.96M -3.21M -1.81M -1.05M
Net income applicable to common shares - - - -1.81M -1.05M
Breakdown 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly yearly yearly
Date 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Total assets 0.80M 1.09M 1.69M 4.35M 3.13M
Other current assets - 0.07M 0.20M - -
Total liab 7.26M 5.38M 3.07M 2.56M 2.56M
Total stockholder equity -6.45M -4.29M -1.38M 1.79M 0.57M
Other current liab - 0.04M 2.20M - -
Common stock - 23.99M 23.99M 23.99M 21.17M
Capital stock 23.99M 23.99M 23.99M 23.99M 21.17M
Retained earnings -34.86M -32.68M -29.72M -26.51M -24.70M
Other assets - 0.00M - 0.51M -
Cash 0.05M 0.17M 0.25M 2.39M 1.72M
Total current liabilities 6.80M 4.80M 2.38M 2.46M 0.38M
Current deferred revenue - 0.00M - - -
Net debt 5.98M 4.89M 0.53M - 0.26M
Short term debt - 4.48M 0.09M - -
Short long term debt 6.03M 4.37M 2.00M 1.93M -
Short long term debt total - 5.06M 0.78M - -
Other stockholder equity - -0.00M - 4.31M 4.10M
Property plant equipment - - - 0.24M 0.37M
Total current assets 0.28M 0.44M 0.90M 3.59M 2.77M
Net tangible assets - - - 1.79M 0.57M
Short term investments - 0.04M 0.04M - -
Net receivables 0.05M 0.03M 0.31M 0.94M 0.78M
Long term debt - - - 0.03M 1.98M
Inventory 0.04M 0.12M 0.09M 0.14M 0.12M
Accounts payable 0.54M 0.27M 0.09M 0.16M 0.16M
Accumulated other comprehensive income - 4.40M 4.35M - -
Non currrent assets other - -0.00M - - -
Non current assets total 0.52M 0.65M 0.79M 0.76M 0.37M
Capital lease obligations 0.58M 0.69M 0.78M 0.23M 0.35M
Breakdown 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly yearly yearly
Date 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Investments 0.04M 0.00M 0.00M -0.51M -0.01M
Change to liabilities - - - 0.14M -0.10M
Total cashflows from investing activities - - - -0.51M -0.01M
Net borrowings 1.49M 2.21M -0.19M -0.15M -0.10M
Total cash from financing activities 1.49M 2.21M -0.19M 2.40M 2.05M
Change to operating activities - - - 0.07M -0.09M
Net income -2.18M -2.96M -3.21M -1.81M -1.05M
Change in cash -0.12M -0.08M -2.14M 0.72M 1.23M
Begin period cash flow 0.17M 0.25M 2.39M 1.72M 0.48M
End period cash flow 0.05M 0.17M 0.25M 2.44M 1.72M
Total cash from operating activities -1.66M -2.29M -1.95M -1.17M -0.80M
Issuance of capital stock - - 0.00M 2.55M 2.16M
Depreciation 0.13M 0.14M 0.13M 0.13M 0.21M
Change to inventory 0.09M -0.03M 0.05M -0.02M -0.12M
Change to account receivables -0.03M 0.28M 0.62M -0.16M -0.22M
Other cashflows from financing activities - 2.37M -0.15M -0.01M -0.34M
Change to netincome - - - 0.48M 0.55M
Capital expenditures 0.00M 0.00M 0.00M 0.00M 0.01M
Change in working capital 0.32M 0.42M 0.45M 0.03M -0.52M
Stock based compensation 0.02M 0.05M 0.04M 0.22M 0.30M
Other non cash items 0.06M 0.12M 0.37M 0.27M 0.25M
Free cash flow -1.66M -2.29M -1.95M -1.18M -0.82M

Peer Comparison*

Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic

Stock Name
Change
(CAD)
Price
(CAD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
RX
Biosyent Inc.		 0.10
0.58%		 17.25 19.10 15.85 3.96 4.11 3.31 11.03
DB
Decibel Cannabis Company Inc		 -
-%		 2.00 - 8.67 0.67 1.20 0.99 17.75
ZYUS
ZYUS Life Sciences Corporation		 -0.03
8.57%		 0.32 - - 108.48 4.41 140.29 -4.26
LSL
LSL Pharma Group Inc.		 -0.01
1.61%		 0.30 20.75 - 1.88 1.89 2.85 10.19

Profile*

Aequus Pharmaceuticals Inc

Aequus Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada. The company offers ZIMED PF, a preservative-free bimatoprost prescription drug for the for the reduction of elevated interocular pressure in patients with open angle glaucoma or ocular hypertension. It also develops REV-0100, which is in pre-clinical trial for the treatment of stargardt disease. Aequus Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in Vancouver, Canada.

200 Granville Street, Vancouver, BC, Canada, V6C 1S4

604 336 7906

https://www.aequuspharma.ca

Name Title Year Born
Mr. Douglas Glen Janzen Chairman, CEO & Pres 1969
Ms. Ann Fehr CGA, CPA CFO & Corp. Sec. 1969
Mr. Stuart Fowler Strategic Commercial Advisor & Independent Director NA
Mr. Grant Larsen Chief Commercial Officer NA
Mr. Douglas Glen Janzen Chairman, CEO & President 1969
Ms. Ann Fehr CGA, CPA CFO & Corporate Secretary 1969
Mr. Rabin Ramanjooloo Chief Operating Officer NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

DHT-U
CAD 13.53
+16.44%
LIF
CAD 22.04
+8.62%
CRON
CAD 5.26
+6.69%
OGC
CAD 38.44
+6.66%
CIA
CAD 2.03
+5.73%
ITH
CAD 1.78
-27.05%
IFOS
CAD 1.62
-24.30%
GIL
CAD 47.38
-21.61%
KEEL
CAD 2.35
-19.80%
TNZ
CAD 51.05
-17.39%

Equity Sectors*

  • Basic Materials

    -2.34%

  • Communication Services

    +0.74%

  • Consumer Cyclical

    -2.81%

  • Consumer Defensive

    -0.87%

  • Energy

    -3.16%

  • Financial Services

    -2.32%

  • Healthcare

    -0.53%

  • Industrials

    -4.40%

  • Real Estate

    -0.43%

  • Technology

    -4.09%

  • Utilities

    -1.03%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…